The combination of survivin shRNA and EGCG markedly decreased angiogenic (VEGF and b-FGF) factors and then inhibited Notch1 expression in neuroblastoma, reasonably inferring that blocking VEGF may enhance the sensitivity of tumors to anti-Notch therapy (Hossain et al., 2012). Here, VEGFA is linked to neuroblastoma.